Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  1992-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.1992.tb00561.xPMID 1358234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine

  1992cited by this paper
• Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.

  1991cited by this paper
• Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazine

  1988cited by this paper
• Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

  1980cited by this paper
• CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS

  1965cited by this paper

• Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase

  2021cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2020cites this paper
• Pharmacotherapy of ulcerative colitis – current status and emerging trends

  2018cites this paper
• Systematic review: safety of mesalazine in ulcerative colitis

  2018cites this paper
• Second Korean guidelines for the management of ulcerative colitis

  2017cites this paper
• [Second Korean Guideline for the Management of Ulcerative Colitis].

  2017cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cites this paper
• Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?

  2015cites this paper
• Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.

  2015cites this paper
• Treatment of Ulcerative colitis in the elderly: A systematic Review

  2013cites this paper
• Balsalazide

  2012cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2012cites this paper
• Balsalazide

  2012cites this paper
• One-year Investigator-blind Randomized Multicenter Trial Comparing Asacol 2.4 g Once Daily with 800 mg Three Times Daily for Maintenance of Remission in Ulcerative Colitis

  2011cites this paper
• Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

  2010cites this paper
• Erratum: Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

  2010cites this paper
• A Stability-Indicating LC Method for Analysis of Balsalazide Disodium in the Bulk Drug and in Pharmaceutical Dosage Forms

  2009cites this paper
• Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study.

  2008cites this paper
• Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics.

  2008cites this paper
• Balsalazide disodium for the treatment of ulcerative colitis

  2008cites this paper
• 5‐Aminosalicylates and renal function in inflammatory bowel disease: A systematic review

  2007cites this paper
• Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis

  2007influential citation
• Inflammatory bowel disease: clinical aspects and established and evolving therapies

  2007cites this paper
• Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.

  2006cites this paper
• Mesalamine delivery systems: do they really make much difference?

  2005cites this paper
• Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.

  2004cites this paper
• Patient‐led variable dosing with balsalazide as long‐term therapy for maintenance in ulcerative colitis: a 3‐year prospective observational study

  2004cites this paper
• Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

  2004cites this paper
• Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.

  2004cites this paper
• Aminosalicylate Treatment in IBD continued ability to inhibit the activation of nuclear factor

  2004cites this paper
• Short‐term adverse effects of 5‐aminosalicylic acid agents in the treatment of ulcerative colitis

  2004cites this paper
• Medical management of ulcerative colitis

  2003cites this paper
• 30 Medical management of ulcerative colitis

  2003cites this paper
• Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

  2002cites this paper
• A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis

  2002cites this paper
• Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

  2002cites this paper
• Review article: monitoring for drug side-effects in inflammatory bowel disease.

  2002cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2002cites this paper
• Monitoring for drug side‐effects in inflammatory bowel disease

  2002cites this paper
• Balsalazideof its Therapeutic Use in Mild-to-Moderate Ulcerative Colitis

  2002cites this paper
• Balsalazide therapy in ulcerative colitis

  2001cites this paper
• 5-Aminosalicylates in inflammatory bowel disease: choosing the right dose.

  2001cites this paper
• Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

  2001cites this paper
• 5-Aminosalicylates in inflammatory bowel: disease: Choosing choosing the right dose

  2001cites this paper
• Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.

  2000cites this paper
• Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

  1999cites this paper
• What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

  1998cites this paper
• Novel approaches to inflammatory bowel disease.

  1998cites this paper
• 5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis.

  1997cites this paper
• 5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis.

  1997cites this paper
• Alternatives to Sulfasalazine: A Meta‐analysis of 5‐ASA in the Treatment of Ulcerative Colitis

  1997cites this paper
• A gastroenterologist’s perspective of the medical management of patients with Crohn’s disease and ulcerative colitis

  1996cites this paper
• Maintenance therapy in ulcerative colitis and Crohn's disease.

  1995cites this paper
• [Current developments in the diagnosis and therapy of Crohn disease and ulcerative colitis].

  1994cites this paper
• Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

  1994cites this paper
• Salicylates for inflammatory bowel disease.

  1994cites this paper
• Salicylates for ulcerative colitis--their mode of action.

  1994cites this paper
• New salicylates as maintenance treatment in ulcerative colitis.

  1994cites this paper
• The treatment of ulcerative colitis with balsalazide sodium

  1993cites this paper